{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -0.23, "sharesOutstanding": 11713200, "fiftyDayAverage": 0.62826, "fiftyDayAverageChange": -0.05226004, "fiftyDayAverageChangePercent": -0.083182186, "twoHundredDayAverage": 0.4584075, "twoHundredDayAverageChange": 0.117592484, "twoHundredDayAverageChangePercent": 0.2565239, "marketCap": 6864595, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "SEK", "regularMarketOpen": 0.576, "averageDailyVolume3Month": 52, "averageDailyVolume10Day": 307, "fiftyTwoWeekLowChange": 0.39199996, "fiftyTwoWeekLowChangePercent": 2.1304345, "fiftyTwoWeekRange": "0.184 - 0.85", "fiftyTwoWeekHighChange": -0.27400005, "fiftyTwoWeekHighChangePercent": -0.32235298, "fiftyTwoWeekLow": 0.184, "fiftyTwoWeekHigh": 0.85, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1613631600000, "priceHint": 4, "marketState": "REGULAR", "regularMarketChange": -0.045000017, "regularMarketTime": 1683872571, "regularMarketDayHigh": 0.576, "regularMarketDayRange": "0.576 - 0.576", "regularMarketDayLow": 0.576, "regularMarketVolume": 3078, "regularMarketPreviousClose": 0.621, "bid": 0.606, "ask": 0.629, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": -7.24638, "regularMarketPrice": 0.576, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "ONCOZENGE AB", "longName": "OncoZenge AB (publ)", "messageBoardId": "finmb_694394254", "market": "dr_market", "symbol": "8LY.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Gustavslundsvagen 34", "city": "Bromma", "zip": "167 51", "country": "Sweden", "phone": "46 8 31 14 20", "website": "https://www.oncozenge.se", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "OncoZenge AB (publ), a pharmaceutical company, develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul  de Potocki M.Sc.", "age": 60, "title": "Chief Exec. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Beveridge", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Pirkko Sulila Tamsen", "age": 63, "title": "Chief Operating Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Markus  Jerling M.D., Ph.D.", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}